PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
03 avr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
30 mars 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium
29 mars 2023 07h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted...
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
28 mars 2023 07h30 HE
|
PDS Biotechnology Corporation
Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor100% (9/9) clinical response (>60% tumor...
The Worldwide Proton Therapy Industry is Expected to Reach $963.6 Million by 2028
12 janv. 2023 04h43 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head &...
Outlook on the Radiation Oncology Global Market to 2028 - Featuring Varian Medical Systems, Ion Beam Applications, Elekta and Accuray Among Others
11 janv. 2023 07h58 HE
|
Research and Markets
Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Oncology Market Size, Share & Industry Trends Analysis Report By Application, By Type (External Beam Radiation Therapy and...
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
04 janv. 2023 08h00 HE
|
Immutep Limited
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
15 déc. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Head And Neck Cancer Therapeutics Market Is Estimated To Grow At CAGR Of 8.5 %, 2022-2028 | Latest Industry Coverage By Douglas Insights
08 nov. 2022 05h08 HE
|
Douglas Insights
Isle Of Man, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Douglas Insights has made the newest addition to their comparison engine. Head and neck cancer therapeutics market research reports can now be compared...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
27 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...